A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative ...

EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced that new clinical data from its non-small cell lung ...

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the ...

Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients. This episode focuses on the strategies for ...

New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves ...

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients ...

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize ...

If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...